PMID- 19954724
OWN - NLM
STAT- MEDLINE
DCOM- 20100223
LR  - 20190608
IS  - 0301-0430 (Print)
IS  - 0301-0430 (Linking)
VI  - 72
IP  - 6
DP  - 2009 Dec
TI  - Altered fibrinolytic activities in gastric cancer and uremic patients after 
      intervention.
PG  - 468-72
AB  - INTRODUCTION: Although thromboembolism is the most recognized cause of death in 
      cancer and uremic patients following tumorectomy or hemodialysis, respectively, 
      little data exist concerning its etiologies and treatments in post-intervention 
      settings. In this study, we determined the post-intervention fibrinolytic 
      activities to exploit their implications in gastric cancer and uremic patients. 
      MATERIALS AND METHODS: A small-scale case-control study with totally 56 cases 
      aimed to compare the difference of the post-intervention fibrinolytic activities 
      of two hypercoagulable groups of gastric cancer and uremic patients versus 
      healthy controls was conducted. In-house functional assays for plasma plasminogen 
      (Pg) and plasminogen activators (PA) activities were employed. RESULTS: As 
      compared to the control, both variable-stratified patient groups disclosed 
      reduced Pg activities, synonyms at the "hypofibrinolytic" state, suggesting that 
      the alleged post-intervention hypercoagulability of the two patient groups could 
      be rationalized by the hypofibrinolysis mechanism. On the other hand, cancer 
      patients showed elevated PA activity, concomitantly implicating that there was 
      associated fibrinolytic consumption. Moreover, the altered PA activity could be 
      ascribed to tumor metastasis according to literature review. CONCLUSIONS: Our 
      data suggested that the PA/Pg fibrinolytic activities were altered in gastric 
      cancer and uremic patients post-interventionally. Measurement of the 
      post-intervention fibrinolytic activities could be useful in projection of some 
      potential risks.
FAU - Chen, J-S
AU  - Chen JS
AD  - Divisions of Nephrology, Tri-Service General Hospital, Taipei, Taiwan.
FAU - Chan, D-C
AU  - Chan DC
FAU - Chung, M-J
AU  - Chung MJ
FAU - Chang, L-C
AU  - Chang LC
FAU - Yang, V C
AU  - Yang VC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Clin Nephrol
JT  - Clinical nephrology
JID - 0364441
RN  - 9001-91-6 (Plasminogen)
RN  - EC 3.4.21.- (Plasminogen Activators)
SB  - IM
MH  - Female
MH  - Fibrinolysis/*physiology
MH  - Follow-Up Studies
MH  - Gastrectomy/*adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Plasminogen/metabolism
MH  - Plasminogen Activators/blood
MH  - Renal Dialysis/*adverse effects
MH  - Retrospective Studies
MH  - Stomach Neoplasms/*blood/therapy
MH  - Thrombosis/blood/*etiology
MH  - Uremia/*blood/therapy
EDAT- 2009/12/04 06:00
MHDA- 2010/02/24 06:00
CRDT- 2009/12/04 06:00
PHST- 2009/12/04 06:00 [entrez]
PHST- 2009/12/04 06:00 [pubmed]
PHST- 2010/02/24 06:00 [medline]
AID - 6796 [pii]
AID - 10.5414/cnp72468 [doi]
PST - ppublish
SO  - Clin Nephrol. 2009 Dec;72(6):468-72. doi: 10.5414/cnp72468.